Becton, Dickinson and Company

610 articles with Becton, Dickinson and Company

• BD Announces Live Webcast Of Fourth Fiscal Quarter 2019 Earnings Conference Call

  10/3/2019

  BD announced that it will conduct a live webcast of its fourth fiscal quarter and full fiscal year 2019 earnings conference call on Tuesday, November 5, 2019, at 8:00 a.m..

• BD Announces Publication of an Independent Analysis of Drug-Coated Balloon Safety Data for Femoropopliteal Peripheral Arterial Disease

  9/28/2019

  Independent analysis of LUTONIX® 035 Drug Coated Balloon patient-level data showed no statistically significant mortality increase

• BD Announces Leadership Succession Plan

  9/26/2019

  BD (Becton, Dickinson and Company) announced that Vincent A. Forlenza, chairman and CEO, will retire as CEO on Jan. 28, 2020, following the company's annual meeting of shareholders.

• BD to Present at Investor Healthcare Conferences - Aug. 21, 2019

  8/21/2019

  BD announced that it will present at the following upcoming investor healthcare conferences

• BD Announces Results For 2019 Third Fiscal Quarter; Reaffirms Fiscal 2019 Guidance

  8/6/2019

  BD, a leading global medical technology company, reported quarterly revenues of $4.350 billion for the third fiscal quarter ended June 30, 2019.

• Top 5 Vendors in the Urethral Dilator Market from 2019 to 2023 | Technavio

  7/24/2019

  The incidence of urethral stricture disease, in which the urethral opening becomes narrow due to genetic disorders, scars, or infections such as STD, is increasing significantly.

• Top 5 Vendors in the Kidney Stones Management Devices Market from 2019 to 2023 | Technavio

  7/24/2019

  With the aim to improve the quality of care and treatment offered to patients suffering from kidney-related conditions, several public and non-profit organizations are taking initiatives such as expert consultations and free screenings.

• BD releases 2018 Sustainability Report

  7/23/2019

  BD, a leading global medical technology company, issued its 2018 Sustainability Report, focusing on management of the environmental, social and governance factors that support the company's 2020 Sustainability Goals.

• BD Board Declares Dividends, payable on September 30, 2019

  7/22/2019

  The Board of Directors of BD has declared a quarterly dividend of $0.77 per common share, payable on September 30, 2019 to holders of record on September 9, 2019.

• BD Provides Update on Voluntary Recalls of Alaris™ Pump Module Model 8100 and Certain Alaris™ Pump Infusion Sets

  7/18/2019

  BD, a leading global medical technology company, provided an update on two voluntary recalls related to certain Alaris™ Pump Modules Model 8100 manufactured between April 2011 and June 2017 and certain model codes and lot numbers of the Alaris™ Pump Infusion Sets used with the Alaris™ Pump Model 8100.

• BD Announces Live Webcast of Third Fiscal Quarter Earnings Conference Call - July 2, 2019

  7/2/2019

  BD announced that it will conduct a live webcast of its third fiscal quarter 2019 earnings conference call on Tuesday, August 6, 2019, at 8:00 a.m..

• BD Statement on FDA Circulatory System Devices Panel Regarding Paclitaxel-Coated Devices

  6/20/2019

  BD, a leading global medical technology company, issued the following statement following the U.S. Food and Drug Administration Circulatory System Devices Panel of the Medical Devices Advisory Committee meeting related to the potential increase in mortality associated with the use of paclitaxel-coated devices in patients with peripheral arterial disease in the superficial femoropopliteal artery

• Vulnerabilities Disclosed by CyberMDX Allow Attackers to Take Over Infusion Pumps

  6/13/2019

  Vulnerabilities found in BD Alaris Gateway Workstation affirmed by ICS-CERT with CVSS scores of 10.0 and 7.3 respectively

• BD Announces Early Tender Results - June 3, 2019

  6/4/2019

  Becton, Dickinson and Company announced the early tender results for its previously announced tender offers to purchase for cash, in the order of priority set forth in the table below, up to the applicable Tender SubCap, if any, of each of the Company's 5.000% Notes due 2040, 4.875% Notes due 2044, 4.685% Notes due 2044, 3.700% Notes due 2027, 3.734% Notes due 2024, 4.669% Notes due 2047 and 2.894% Notes due 2022

• Becton, Dickinson and Company Announces Tender Offers for Outstanding Debt Securities - May 20, 2019

  5/20/2019

  Becton, Dickinson and Company announced that it has commenced tender offers to purchase for cash the debt securities issued by the Company listed in the table below.

• BD Announces Results for 2019 Second Fiscal Quarter; Updates Fiscal 2019 Guidance

  5/9/2019

  The company reaffirmed its full fiscal year 2019 comparable, currency-neutral revenue guidance, and updated its adjusted diluted earnings per share guidance.

• BD to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference

  5/1/2019

  BD announced that it will present at the Bank of America Merrill Lynch 2019 Global Healthcare Conference on Tuesday, May 14, 2019, at 10:00 a.m. ET.

• BD Receives FDA Approval for Fully Sterile Chlorhexidine Gluconate Antiseptic Skin Preparation

  4/30/2019

  New BD ChloraPrep™ Skin Preparation is the Only Commercially Available CHG Antiseptic Skin Preparation with Sterile Solution Designation in the U.S.

• BD Board Declares Dividends, payable on June 28, 2019

  4/29/2019

  The Board of Directors of BD has declared a quarterly dividend of $0.77 per common share, payable on June 28, 2019 to holders of record on June 7, 2019.

• BD Unveils Platelet Quality Control Media to Help Reduce the Incidence of Sepsis in Patients Requiring Platelet Transfusion

  4/8/2019

  BD BACTEC™ Platelet Quality Control Media is cleared by the U.S. Food and Drug Administration and CE-IVD marked for platelet testing